Synapse - Works

Results (4925)

Myeloid malignancies following luminal gastrointestinal cancer: High incidence of deletion 5q and DNTM3A mutations

Meeting Abstract

Epstein-Peterson, Z. D.; Devlin, S. M.; Stein, E. M.; Klimek, V. M.; Saltz, L. B.; Tallman, M. S.
Blood (2017)

Prognostic role of gene mutations in chronic myelomonocytic leukemia (CMML) patients treated with hypomethylating agents: A report on 183 patients

Meeting Abstract

Duchmann, M.; Yalniz, F.; Sanna, A.; Sallman, D. A.; Coombs, C. C.; Renneville, A.; Kosmider, O.; Braun, T.; Platzbecker, U.; Willems, L.; more...
Blood (2017)

Fulltext@MSK | Save

Single-arm phase II trial of pegylated interferon alpha 2a in patients with high-risk essential thrombocythemia or polycythemia vera resistant or intolerant to hydroxyurea: MPN symptom impact & quality of life results of the Myeloproliferative Disorders-Research Consortium (MPD-RC) protocol 111 global phase II trial

Meeting Abstract

Dueck, A. C.; Mascarenhas, J.; Kosiorek, H. E.; Yacoub, A.; Prchal, J. T.; Berenzon, D.; Baer, M. R.; Ritchie, E. K.; Silver, R. T.; Kessler, C. M.; more...
Blood (2017)

Fulltext@MSK | Save

Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients with acute myeloid leukemia (AML) treated within the international ratify study

Meeting Abstract

Döhner, K.; Thiede, C.; Larson, R. A.; Prior, T. W.; Marcucci, G.; Jones, D.; Krauter, J.; Heuser, M.; Lo Coco, F.; Ottone, T.; more...
Blood (2017)

Fulltext@MSK | Save

A phase I study of FLX925, a dual FLT3 and CDK4/6 inhibitor in patients with relapsed or refractory acute myeloid leukemia (AML)

Meeting Abstract

Daver, N.; Pollyea, D. A.; Rizzieri, D. A.; Palmer, J.; Rampal, R. K.; Dinner, S.; Bixby, D. L.; Percival, M. E. M.; Kovacsovics, T.; Begna, K. H.; more...
Blood (2017)

Fulltext@MSK | Save

Final analysis of the phase I/II study of CC-486 (oral azacitidine) maintenance therapy after allogeneic stem cell transplantation (allo-SCT) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)

Meeting Abstract

de Lima, M.; Oran, B.; Champlin, R. E.; Papadopoulos, E. B.; Giralt, S. A.; Scott, B. L.; William, B. M.; Hetzer, J.; Hubbell, B.; Skikne, B. S.; more...
Blood (2017)

Fulltext@MSK | Save

Risk of hyponatremia and associated clinical characteristics in patients with acute lymphoblastic leukemia after CD19 targeted chimeric antigen receptor (CAR) T-cells

Meeting Abstract

Dixon, B. N.; Daley, R. J.; Horvat, T. Z.; Buie, L. W.; Hsu, M.; Latcha, S.; Brentjens, R. J.; Park, J. H.
Blood (2017)

Fulltext@MSK | Save

A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: Results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML)

Meeting Abstract

Dawson, M.; Stein, E. M.; Huntly, B. J. P.; Karadimitris, A.; Kamdar, M.; de Larrea, C. F.; Dickinson, M. J.; Yeh, P. S. H.; Daver, N.; Chaidos, A.; more...
Blood (2017)

Fulltext@MSK | Save

Phase 2 trial of single-agent cobimetinib for adults with BRAF V600-mutant and wild-type histiocytic disorders

Meeting Abstract

Diamond, E. L.; Durham, B. H.; Dogan, A.; Hyman, D. M.; Rampal, R. K.; Ulaner, G.; Brody, L.; Abdel-Wahab, O.
Blood (2017)

Fulltext@MSK | Save

Long-term cardiac, vascular and hypertensive safety of bosutinib in patients with Philadelphia chromosome-positive (Ph+) leukemia resistant or intolerant to prior therapy

Meeting Abstract

Cortes, J. E.; Kim, D. W.; Kantarjian, H. M.; Mauro, M. J.; Aguiar, J. M.; An, F.; Leip, E.; Gambacorti-Passerini, C.; Brummendorf, T. H.
Blood (2017)

Fulltext@MSK | Save